Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Mersana Therapeutics Inc MRSN

Healthcare Biotechnology
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development of antibody-drug conjugates (ADCs), which offer a clinically meaningful benefit for cancer patients with significant unmet needs. It has developed two proprietary and differentiated ADC platforms: Dolasynthen and Immunosynthen. Dolasynthen is its cytotoxic ADC platform that is designed... see more

Recent & Breaking News (NDAQ:MRSN)

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire January 6, 2023

Mersana Therapeutics Provides Business Update and Announces Strategic Objectives and Expected Milestones

GlobeNewswire January 6, 2023

Mersana Therapeutics Announces Research Collaboration and Commercial License Agreement with Merck KGaA, Darmstadt, Germany to Develop Novel Immunosynthen Antibody-Drug Conjugates

GlobeNewswire December 22, 2022

European Commission Designates UpRi as an Orphan Medicinal Product for the Treatment of Ovarian Cancer

GlobeNewswire December 14, 2022

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire December 2, 2022

Mersana Therapeutics to Present at Jefferies London Healthcare Conference

GlobeNewswire November 8, 2022

Mersana Therapeutics Provides Business Update and Announces Third Quarter 2022 Financial Results

GlobeNewswire November 7, 2022

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire November 4, 2022

Mersana Therapeutics to Host Third Quarter 2022 Conference Call on November 7, 2022

GlobeNewswire October 31, 2022

Mersana Therapeutics Announces Completion of Enrollment in UPLIFT, a Single-Arm Registrational Trial of Upifitamab Rilsodotin (UpRi) in Platinum-Resistant Ovarian Cancer

GlobeNewswire October 6, 2022

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire October 4, 2022

Mersana Therapeutics Announces Launch of Oncology FACETS, a Resource for Healthcare Providers to Advance Knowledge in Gynecologic Malignancies

GlobeNewswire September 30, 2022

Mersana Therapeutics Announces FDA Fast Track Designation Granted to XMT-1660 for the Treatment of Triple-Negative Breast Cancer

GlobeNewswire September 12, 2022

Mersana Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire September 6, 2022

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire September 2, 2022

Mersana Therapeutics Announces Initiation of Phase 1 Trial of XMT-1660 in Breast, Endometrial and Ovarian Cancers

GlobeNewswire August 16, 2022

Mersana Therapeutics Provides Business Update and Announces Second Quarter 2022 Financial Results

GlobeNewswire August 8, 2022

Mersana Therapeutics Announces Option Agreement with GSK for the Co-Development and Commercialization of XMT-2056, an Immunosynthen ADC Targeting HER2

GlobeNewswire August 8, 2022

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire August 4, 2022

Mersana Therapeutics to Host Second Quarter 2022 Conference Call on August 8, 2022 and Present at Upcoming Conferences

GlobeNewswire August 3, 2022